Last reviewed · How we verify
NELMASTOBART
At a glance
| Generic name | NELMASTOBART |
|---|---|
| Modality | Monoclonal antibody |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer (PHASE2)
- Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer (PHASE1, PHASE2)
- Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NELMASTOBART CI brief — competitive landscape report
- NELMASTOBART updates RSS · CI watch RSS